Trial Profile
RE-VOLUTION: The RE-SOLVE study. Dabigatran etexilate in the secondary prevention of venous thromboembolism
Status:
Not stated
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2006
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Thromboembolism
- Focus Registrational; Therapeutic Use
- Acronyms RE-SOLVE; RE-VOLUTION
- Sponsors Boehringer Ingelheim
- 31 Jan 2006 New trial record.